Rodorubicin
| Code | Size | Price |
|---|
| TAR-T26113-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Rodorubicin is a novel tetraglycosidic anthracycline with antitumor activity.
CAS:
96497-67-5
Formula:
C48H64N2O17
Molecular Weight:
941.037
Purity:
0.98
SMILES:
[H][C@]12C[C@H](O[C@@H]3[C@H](C)O[C@H](C[C@@H]3N(C)C)O[C@H]3C[C@](O)(CC)[C@H](O[C@H]4C[C@@H]([C@H](O)[C@H](C)O4)N(C)C)c4c(O)c5C(=O)c6cccc(O)c6C(=O)c5c(O)c34)O[C@@H](C)[C@@]1([H])O[C@]1([H])O[C@@H](C)C(=O)C[C@@]1([H])O2
References
1. Kraemer HP, Sedlacek HH. Rodorubicin, a new tetraglycosidic anthracycline. Behring Inst Mitt. 1988 Apr;(82):216-30. PubMed PMID: 3165634.
2. Verweij J, van der Burg ME, van Putten WL, Henzen-Logmans SC, Salewski E, Kraemer HP, Stoter G. Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors. Eur J Cancer Clin Oncol. 1989 Apr;25(4):627-32. PubMed PMID: 2714339.
3. Hermentin P, Doenges R, Gronski P, Bosslet K, Kraemer HP, Hoffmann D, Zilg H, Steinstraesser A, Schwarz A, Kuhlmann L, et al. Attachment of rhodosaminylanthracyclinone-type anthracyclines to the hinge region of monoclonal antibodies. Bioconjug Chem. 1990 Mar-Apr;1(2):100-7. PubMed PMID: 2095207.
4. Iwahashi T, Tone Y, Usui J, Watanabe H, Sugawara I, Mori S, Okazaki H. Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208. Cancer Immunol Immunother. 1989;30(4):239-46. PubMed PMID: 2598192.